BTIG Research Cuts Boston Scientific (NYSE:BSX) Price Target to $56.00

Boston Scientific (NYSE:BSX) had its price target cut by BTIG Research from $60.00 to $56.00 in a research note published on Wednesday, Marketbeat Ratings reports. They currently have a buy rating on the medical equipment provider’s stock.

A number of other equities analysts have also recently weighed in on BSX. Needham & Company LLC decreased their price target on Boston Scientific from $77.00 to $57.00 and set a “buy” rating for the company in a report on Wednesday, July 8th. Weiss Ratings downgraded shares of Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, July 7th. Robert W. Baird set a $56.00 price target on shares of Boston Scientific in a research note on Thursday, July 30th. Leerink Partners set a $60.00 price objective on shares of Boston Scientific in a research report on Thursday, July 30th. Finally, Zacks Research lowered Boston Scientific from a “hold” rating to a “strong sell” rating in a research report on Friday, June 5th. Twenty-four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and a consensus target price of $71.46.

Boston Scientific Stock Performance

NYSE:BSX opened at $43.00 on Wednesday. The firm’s fifty day simple moving average is $47.00 and its 200 day simple moving average is $54.66. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. Boston Scientific has a twelve month low of $42.20 and a twelve month high of $105.65. The firm has a market capitalization of $62.31 billion, a price-to-earnings ratio of 17.41, a PEG ratio of 1.00 and a beta of 0.57.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm’s revenue was up 7.5% compared to the same quarter last year. During the same period last year, the company posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities research analysts expect that Boston Scientific will post 3.29 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has initiated a share repurchase plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

Insider Activity at Boston Scientific

In other news, CEO Michael Mahoney bought 186,240 shares of Boston Scientific stock in a transaction on Monday, August 3rd. The shares were bought at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the acquisition, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This represents a 13.27% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David Habiger purchased 2,100 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the transaction, the director owned 17,160 shares in the company, valued at approximately $816,644.40. This represents a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 194,522 shares of company stock valued at $9,385,210 over the last three months. 0.34% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Brighton Jones LLC lifted its position in Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after purchasing an additional 226 shares during the last quarter. FWL Investment Management LLC bought a new stake in Boston Scientific during the 2nd quarter valued at $26,000. Main Street Financial Solutions LLC grew its stake in shares of Boston Scientific by 35.3% in the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after purchasing an additional 1,971 shares in the last quarter. Ieq Capital LLC raised its stake in shares of Boston Scientific by 97.0% during the second quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock valued at $13,275,000 after purchasing an additional 60,860 shares in the last quarter. Finally, HUB Investment Partners LLC lifted its holdings in Boston Scientific by 56.2% in the second quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock worth $763,000 after purchasing an additional 2,556 shares during the period. 89.07% of the stock is currently owned by institutional investors.

About Boston Scientific

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company’s products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.